{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-25-000099","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2025-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.957270+00:00","generated_at":"2026-05-20T04:27:51.065153+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Summit's ivonescimab meets PFS endpoint in global Phase III HARMONi; OS trend positive","bullets":["Ivonescimab + chemo reduced risk of progression or death by 48% vs chemo alone (HR 0.52; p<0.00001).","Overall survival showed positive trend (HR 0.79; p=0.057), not statistically significant.","No new safety signals; Grade 3+ TEAEs 56.9% ivonescimab arm vs 50.0% control.","Summit plans to file BLA with FDA but notes FDA requires statistically significant OS benefit.","Consistent PFS benefit observed across Asia and ex-Asia (including North America) sub-populations."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-25-000099","json":"https://secwatch.observer/filing/0001599298-25-000099.json","markdown":"https://secwatch.observer/filing/0001599298-25-000099.md","text":"https://secwatch.observer/filing/0001599298-25-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000099/0001599298-25-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000099/smmt-20250530.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T04:27:51.065153+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}